On February 27, 2018, Zydus Pharma received FDA approval for ANDA206798, signaling a significant opportunity to capture market share in the undetermined therapeutic segment following the patent expiration of the reference Listed Drug. The approval marks a strategic expansion for the manufacturer in the sector, poised to leverage increased generic accessibility to drive revenue growth and consumer adoption.